Name: AC IMMUNE SA (ACIU) Stock
Brand: AC IMMUNE SA
Rating: 4.5 (3 reviews)

ACIU Latest News, Press Relases and Analysis

All

Press Releases

23 days ago - By: AC Immune SA

AC Immune to Present at the Jefferies 2025 London Healthcare Conference

a month ago - By: Zacks Investment Research - Mentions: DARE

AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates

a month ago - By: AC Immune SA

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

a month ago - By: AC Immune SA

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

a month ago - By: Zacks Investment Research - Mentions: ALEC

Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

4 months ago - By: Zacks Investment Research - Mentions: ABEV ALX

New Strong Sell Stocks for August 6th

a month ago - By: AC Immune SA

AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board

a month ago - By: AC Immune SA

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine

a month ago - By: AC Immune SA

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine

2 months ago - By: Benzinga - Mentions: BFLY RLMD AQB LPTX ...

12 Health Care Stocks Moving In Friday's Intraday Session

2 months ago - By: Benzinga - Mentions: CCCC DBVT CLPT OVID ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

2 months ago - By: AC Immune SA

Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine

2 months ago - By: AC Immune SA

Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine

3 months ago - By: AC Immune SA

AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway

3 months ago - By: AC Immune SA

AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway

4 months ago - By: Zacks Investment Research - Mentions: FTRE

AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: AC Immune SA

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

4 months ago - By: AC Immune SA

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

4 months ago - By: Zacks Investment Research - Mentions: ANAB

AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

7 months ago - By: AC Immune SA

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

7 months ago - By: AC Immune SA

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

8 months ago - By: AC Immune SA

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

8 months ago - By: AC Immune SA

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

8 months ago - By: AC Immune SA

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

8 months ago - By: AC Immune SA

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

9 months ago - By: AC Immune SA

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

9 months ago - By: AC Immune SA

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

9 months ago - By: AC Immune SA

AC Immune to Participate in Upcoming Investor Conferences

a year ago - By: AC Immune SA

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

a year ago - By: AC Immune SA

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

a year ago - By: AC Immune SA

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

a year ago - By: AC Immune SA

AC Immune to Present at the Jefferies 2024 London Healthcare Conference

a year ago - By: AC Immune SA

AC Immune to Present at the Jefferies 2024 London Healthcare Conference

a year ago - By: AC Immune SA

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

a year ago - By: AC Immune SA

AC IMMUNE SA (ACIU) Stock News

ACIU Latest News, Press Relases and Analysis